A hydrogenation method for preparing HBPA includes placing a BPA reaction liquid into a hydrogenation vessel with a hollow-shaft stirrer installed inside; starting the hollow-shaft stirrer to stir the BPA reaction liquid and simultaneously allowing hydrogen gas evenly distributed over and contact well with the BPA reaction liquid; in the presence of a single-metallic Ru/Al2O3 hydrogenation catalyst to proceed with a catalytic hydrogenation at low temperature and low pressure to produce HBPA, the HBPA has a yield of 99.7% or more, and particularly having a trans/trans isomer ratio above 63%.

A hydrogenation method for preparing HBPA includes placing a BPA reaction liquid into a hydrogenation vessel with a hollow-shaft stirrer installed inside; starting the hollow-shaft stirrer to stir the BPA reaction liquid and simultaneously allowing hydrogen gas evenly distributed over and contact well with the BPA reaction liquid; in the presence of a single-metallic Ru/Al2O3 hydrogenation catalyst to proceed with a catalytic hydrogenation at low temperature and low pressure to produce HBPA, the HBPA has a yield of 99.7% or more, and particularly having a trans/trans isomer ratio above 63%.

Compounds of formula (I): where R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6 and R.sup.7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. ##STR00001##

The present disclosure is concerned with methods of making hydroxy derivatives of vitamin D.sub.3, compounds useful as intermediates in the preparation of the hydroxy derivatives, and methods of making the intermediates. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with methods of making hydroxy derivatives of vitamin D.sub.3, compounds useful as intermediates in the preparation of the hydroxy derivatives, and methods of making the intermediates. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Disclosed are substituted (4-hydroxylphenyl) cycloalkane compounds and substituted (4-hydroxylphenyl) cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ER?). The disclosed compounds may be formulated as pharmaceutical compositions and administered for treating diseases associated with ER activity, such as neurological, psychiatric, and/or cell proliferative diseases and disorders as well as for enhancing memory consolidation in subjects in need thereof.

Disclosed are substituted (4-hydroxylphenyl) cycloalkane compounds and substituted (4-hydroxylphenyl) cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ER?). The disclosed compounds may be formulated as pharmaceutical compositions and administered for treating diseases associated with ER activity, such as neurological, psychiatric, and/or cell proliferative diseases and disorders as well as for enhancing memory consolidation in subjects in need thereof.

A catalyst is provided. The catalyst includes a carrier and a metal. The carrier is represented by a formula: M.sub.xAl.sub.(1-x)O.sub.(3-x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal is loaded on the carrier. A method for manufacturing the catalyst is also provided.

A catalyst is provided. The catalyst includes a carrier and a metal. The carrier is represented by a formula: M.sub.xAl.sub.(1-x)O.sub.(3-x)/2, where M is an alkaline earth metal, and x is between 0.09 and 0.24. The metal is loaded on the carrier. A method for manufacturing the catalyst is also provided.

Compounds of formula (II):

##STR00001##

wherein

##STR00002##

R.sup.1, R.sup.2, R.sup.5 and R.sup.13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.